Method Profile
Measure dose-response viability in untreated tumor-derived ovarian organoids and compare with defined chemotherapy or PARP-maintenance outcomes.
Explore functional drug sensitivity alongside histology/genomics in ovarian cancer.
21 organoid lines from 30 treatment-naive epithelial ovarian cancer specimens, with multiple successfully established histologies.
384-well cultures; drug added 48 hours after seeding at six concentrations; six-day exposure followed by CellTiter-Glo 3D; technical triplicates.
Models
Patient-derived epithelial ovarian cancer organoids in GFR Matrigel.
Agents and endpoints
Carboplatin, paclitaxel, olaparib, niraparib; vehicle/staurosporine controls; ATP viability, dose-response and IC50.
Thirty tumors yielded 21 cultures; chemotherapy response testing involved 20 treated patients with 12 evaluable outcomes, and PARP testing involved 10 cultures. Outcomes use the study’s evaluability and duration definitions.
Compare organoid sensitivity with first-line chemotherapy and selected PARP maintenance outcomes.
12 evaluable chemotherapy cases from 20 treated patients; 10 PARP-tested organoids; 21 successfully established cultures overall.
Clinical response groups and genomic BRCA/HRD status; within-assay vehicle and positive controls.
Chemotherapy accuracy 91.67% (95% CI 61.52–99.79%); sensitivity 100% (95% CI 62.88–100%), specificity 66.67% (95% CI 12.53–98.23%). Selected PARP examples disagreed with genomic expectation but aligned with reported outcomes.
A single-center study established 21 organoid cultures from 30 untreated ovarian cancers. Chemotherapy comparisons used 12 evaluable cases; selected PARP-inhibitor examples showed agreement with outcomes despite discordance with genomic HRD status.
